Evidence map›Paper›PMID 35271656›Full record

ArticlePloS one2022

Pan-genome and resistome analysis of extended-spectrum ß-lactamase-producing Escherichia coli: A multi-setting epidemiological surveillance study from Malaysia.

Jacky Dwiyanto, Jia Wei Hor, Daniel Reidpath, Tin Tin Su, Shaun Wen Huey Lee, Qasim Ayub, Faizah Binti Mustapha, Sui Mae Lee, Su Chern Foo, Chun Wie Chong and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Resistance genomics and molecular epidemiology of high-risk clones of ESBL-producingFrontiers in cellular and infection microbiology · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jacky DwiyantoSchool of Science, Monash University Malaysia, Bandar Sunway, Malaysia.ORCID 0000-0002-1224-5553
Jia Wei HorDepartment of Medicine, University of Malaya, Kuala Lumpur, Malaysia.ORCID 0000-0002-8306-5453
Daniel ReidpathHealth System and Population Studies Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
Tin Tin SuSouth East Asia Community Observatory, Segamat, Malaysia.
Shaun Wen Huey LeeSchool of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia.
Qasim AyubSchool of Science, Monash University Malaysia, Bandar Sunway, Malaysia.ORCID 0000-0003-3291-0917
Faizah Binti MustaphaDepartment of Pathology, Hospital Segamat, Segamat, Malaysia.
Sui Mae LeeSchool of Science, Monash University Malaysia, Bandar Sunway, Malaysia.
Su Chern FooSchool of Science, Monash University Malaysia, Bandar Sunway, Malaysia.ORCID 0000-0002-7994-4391
Chun Wie ChongSchool of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia.
Sadequr RahmanSchool of Science, Monash University Malaysia, Bandar Sunway, Malaysia.
Monash University Malaysia · MYInternational Centre for Diarrhoeal Disease Research · BDUniversity of Malaya · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study profiled the prevalence of extended-spectrum ß-lactamase-producing Escherichia coli (ESBL-EC) in the community and compared their resistome and genomic profiles with isolates from clinical patients through whole-genome sequencing.

methodsFecal samples from 233 community dwellers from Segamat, a town in southern Malaysia, were obtained between May through August 2018. Putative ESBL strains were screened and tested using antibiotic susceptibility tests. Additionally, eight clinical ESBL-EC were obtained from a hospital in the same district between June through October 2020. Whole-genome sequencing was then conducted on selected ESBL-EC from both settings (n = 40) for pan-genome comparison, cluster analysis, and resistome profiling.

resultsA mean ESBL-EC carriage rate of 17.82% (95% CI: 10.48%- 24.11%) was observed in the community and was consistent across demographic factors. Whole-genome sequences of the ESBL-EC (n = 40) enabled the detection of multiple plasmid replicon groups (n = 28), resistance genes (n = 34) and virulence factors (n = 335), with no significant difference in the number of genes carried between the community and clinical isolates (plasmid replicon groups, p = 0.13; resistance genes, p = 0.47; virulence factors, p = 0.94). Virulence gene marker analysis detected the presence of extraintestinal pathogenic E. coli (ExPEC), uropathogenic E. coli (UPEC), and enteroaggregative E. coli (EAEC) in both the community and clinical isolates. Multiple blaCTX-M variants were observed, dominated by blaCTX-M-27 (n = 12), blaCTX-M-65 (n = 10), and blaCTX-M-15 (n = 9). The clinical and community isolates did not cluster together based on the pan-genome comparison, suggesting isolates from the two settings were clonally unrelated. However, cluster analysis based on carried plasmids, resistance genes and phenotypic susceptibility profiles identified four distinct clusters, with similar patterns between the community and clinical isolates.

conclusionESBL-EC from the clinical and community settings shared similar resistome profiles, suggesting the frequent exchange of genetic materials through horizontal gene transfer.

Indexed as

Escherichia coliEscherichia coli InfectionsAnti-Bacterial Agentsbeta-LactamasesHumansMalaysiaMicrobial Sensitivity TestsPlasmidsVirulence FactorsAnti-Bacterial Agentsbeta-LactamasesVirulence Factors

Identifiers

PMID35271656
PMCPMC8912130
OpenAlexW4221078622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.